Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Landmark trials in lipid reduction.

W V Brown1

  • 1Atlanta VA Medical Center, Decatur, GA 30033, USA.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|May 6, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selective herbivory by Christmas beetles in response to intraspecific variation in Eucalyptus terpenoids.

Oecologia·2017
Same author

Dihydromatricariate-based triglycerides, glyceride ethers, and waxes in the australian soldier beetle,Chauliognathus lugubris (Coleoptera: Cantharidae).

Journal of chemical ecology·2013
Same author

Novel internally branched, internal alkenes as major components of the cuticular hydrocarbons of the primitive australian antNothomyrmecia macrops Clark (Hymenoptera: Formicidae).

Journal of chemical ecology·2013
Same author

Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with Type 2 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2011
Same author

Cardiovascular disease and lipoproteins: available evidence and remaining questions. Reactor panel and open forum.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2006
Same author

Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.

HIV medicine·2005
Same journal

Development and Validation of a Brief Healthcare Insecurity Scale in a Sample of U.S. Adults Living with and without HIV.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

A Competency Framework for Health Technology Assessment Expertise: Results from a Delphi Study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Physician-led Switching from Reference Biologics to Biosimilars: What is the Effect on selected Health-Related Outcomes and Costs for IBD Patients in Germany?

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020-2023).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Interpreting the Economic Value of TPEx in Recurrent or Metastatic HNSCC: The Importance of Decision Context, Utility Timing, and Treatment Burden.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Development, use and psychometric properties of vision and hearing bolt-ons for EQ-5D-3L and EQ-5D-5L: a systematic review.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
See all related articles

Lipid-lowering therapies significantly reduce cardiovascular events in coronary heart disease patients. Recent trials confirm reduced coronary death rates with cholesterol reduction, aiding primary prevention in high LDL cholesterol individuals.

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Lipid Metabolism

Background:

  • Epidemiological evidence supports lipid reduction for coronary heart disease (CHD) benefits.
  • Landmark trials consistently demonstrate efficacy of lipid-lowering therapies in reducing cardiovascular events.

Purpose of the Study:

  • To synthesize current evidence on the impact of lipid reduction on cardiovascular outcomes.
  • To address remaining questions regarding lipid intervention's effect on mortality and primary prevention.

Main Methods:

  • Review of major clinical trials and epidemiological studies on lipid-lowering therapies.
  • Analysis of data concerning cardiovascular event reduction and mortality rates.

Main Results:

Related Experiment Videos

  • Lipid-lowering therapies significantly reduce major cardiovascular events in patients with high and moderate low-density lipoprotein (LDL) cholesterol.
  • Recent trials confirm a decrease in coronary death rates following plasma cholesterol reduction.
  • Primary prevention shows benefits for high LDL cholesterol, with more data needed for moderate levels.

    • Conclusions:

    • Lipid reduction is a proven strategy for secondary prevention in coronary patients.
    • Further research is required to fully elucidate benefits for primary prevention and cholesterol levels below normal.
    • Ongoing research will optimize patient outcomes through lipid interventions.